Literature DB >> 9852567

A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor.

G L Snyder1, A A Fienberg, R L Huganir, P Greengard.   

Abstract

We have investigated the mechanism by which activation of dopamine (DA) receptors regulates the glutamate sensitivity of medium spiny neurons of the nucleus accumbens. Our results demonstrate that DA regulates the phosphorylation state of the NR1 subunit of NMDA-type glutamate receptors. The effect of DA was mimicked by SKF82526, a D1-type DA receptor agonist, and by forskolin, an activator of cAMP-dependent protein kinase (PKA), and was blocked by H-89, a PKA inhibitor. These data indicate that DA increases NR1 phosphorylation through a PKA-dependent pathway. DA-induced phosphorylation of NR1 was blocked in mice bearing a targeted deletion of the gene for dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32), a phosphoprotein that is a potent and selective inhibitor of protein phosphatase-1, indicating that the effect of PKA is mediated, in part, by regulation of the DARPP-32/protein phosphatase-1 cascade. In support of this interpretation, NR1 phosphorylation was increased by calyculin A, a protein phosphatase-1/2A inhibitor. A model is proposed in which the ability of DA to regulate NMDA receptor sensitivity is attributable to a synergistic action involving increased phosphorylation and decreased dephosphorylation of the NR1 subunit of the NMDA receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9852567      PMCID: PMC6793330     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  35 in total

1.  DARPP-32: regulator of the efficacy of dopaminergic neurotransmission.

Authors:  A A Fienberg; N Hiroi; P G Mermelstein; W Song; G L Snyder; A Nishi; A Cheramy; J P O'Callaghan; D B Miller; D G Cole; R Corbett; C N Haile; D C Cooper; S P Onn; A A Grace; C C Ouimet; F J White; S E Hyman; D J Surmeier; J Girault; E J Nestler; P Greengard
Journal:  Science       Date:  1998-08-07       Impact factor: 47.728

2.  Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites.

Authors:  A S Leonard; J W Hell
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1.

Authors:  H C Hemmings; P Greengard; H Y Tung; P Cohen
Journal:  Nature       Date:  1984 Aug 9-15       Impact factor: 49.962

5.  Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit.

Authors:  M D Ehlers; S Zhang; J P Bernhadt; R L Huganir
Journal:  Cell       Date:  1996-03-08       Impact factor: 41.582

6.  The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses.

Authors:  T Blank; I Nijholt; U Teichert; H Kügler; H Behrsing; A Fienberg; P Greengard; J Spiess
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

7.  Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium.

Authors:  C Konradi; J C Leveque; S E Hyman
Journal:  J Neurosci       Date:  1996-07-01       Impact factor: 6.167

8.  Bidirectional regulation of DARPP-32 phosphorylation by dopamine.

Authors:  A Nishi; G L Snyder; P Greengard
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

9.  Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization.

Authors:  M E Wolf; M Jeziorski
Journal:  Brain Res       Date:  1993-06-11       Impact factor: 3.252

10.  Mammalian brain phosphoproteins as substrates for calcineurin.

Authors:  M M King; C Y Huang; P B Chock; A C Nairn; H C Hemmings; K F Chan; P Greengard
Journal:  J Biol Chem       Date:  1984-07-10       Impact factor: 5.157

View more
  100 in total

1.  Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons.

Authors:  A N Schoffelmeer; L J Vanderschuren; T J De Vries; F Hogenboom; G Wardeh; A H Mulder
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo.

Authors:  G L Snyder; P B Allen; A A Fienberg; C G Valle; R L Huganir; A C Nairn; P Greengard
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

Review 3.  NMDA receptors in the basal ganglia.

Authors:  P Ravenscroft; J Brotchie
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

Review 4.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 5.  Biochemical modulation of NMDA receptors: role in conditioned taste aversion.

Authors:  Beatriz Jiménez; Ricardo Tapia
Journal:  Neurochem Res       Date:  2004-01       Impact factor: 3.996

6.  Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex.

Authors:  Guojun Chen; Paul Greengard; Zhen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

7.  Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain.

Authors:  Hongwen Zhu; Jennifer J O'Brien; James P O'Callaghan; Diane B Miller; Qiang Zhang; Minal Rana; Tiffany Tsui; Youyi Peng; John Tomesch; Joseph P Hendrick; Lawrence P Wennogle; Gretchen L Snyder
Journal:  Brain Res       Date:  2010-04-25       Impact factor: 3.252

8.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

Review 9.  A scale-free systems theory of motivation and addiction.

Authors:  R Andrew Chambers; Warren K Bickel; Marc N Potenza
Journal:  Neurosci Biobehav Rev       Date:  2007-05-03       Impact factor: 8.989

10.  Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex.

Authors:  Yan-Chun Li; Dong Xi; Joy Roman; Yue-Qiao Huang; Wen-Jun Gao
Journal:  J Neurosci       Date:  2009-12-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.